We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
- Authors
Shah, Manish A.; Cho, Jae‐Yong; Tan, Iain B.; Tebbutt, Niall C.; Yen, Chia‐Jui; Kang, Alice; Shames, David S.; Bu, Lilian; Kang, Yoon‐Koo
- Abstract
Background. The phase II YO28252 study (NCT01590719) examined first-line onartuzumab plus mFOLFOX6 in patients with metastatic, human epidermal growth factor receptor 2-negative adenocarcinoma of the stomach or gastroesophageal junction. MET immunohistochemistry expression as a biomarker of onartuzumab activity was also examined. Patients and Methods. Patients were randomized 1:1 to receive standard mFOLFOX6 plus onartuzumab (10 mg/kg) or placebo in 2-week cycles for 12 cycles, followed by onartuzumab or placebo until disease progression. Coprimary endpoints were progression-free survival (PFS) in intent-to-treat (ITT) and MET-positive populations. The target hazard ratio (HR) was 0.70 for patients in the ITT group and 0.60 in the M ET-positive population. Secondary endpoints were overall survival (OS), overall response rate (ORR), and safety. Results. Overall, 123 patients were enrolled (n = 62 onartuzumab, n = 61 placebo). Median PFS was 6.77 versus 6.97 months for onartuzumab versus placebo, respectively (HR, 1.08; 95% confidence interval [CI], 0.71-1.63; p = .71). In the MET-positive population, median PFS was 5.95 versus 6.80 months, onartuzumab versus placebo (HR, 1.38; 95% CI, 0.60-3.20; p = .45). Median OS was 10.61 months for onartuzumab versus 11.27 months for placebo) (HR, 1.06, 0.64-1.75; p = .83). In the MET-positive population, median OS was 8.51 versus 8.48 months for onartuzumab versus placebo, respectively (HR, 1.12, 95% CI, 0.45-2.78; p = .80). ORR was 60.5% for the onartuzumab group and 57.1% for placebo. Grade 3-5 adverse events (AEs) were seen in 88.3% of patients receiving onartuzumab and in 78.3% of patients receiving placebo, with serious AEs in 55% and 40%, respectively. Conclusion. The addition of onartuzumab to mFOLFOX6 in gastric cancer did not improve efficacy in an unselected population or in a MET immunohistochemistry-positive population.
- Subjects
THERAPEUTIC use of monoclonal antibodies; ADENOCARCINOMA; ANTINEOPLASTIC agents; CELLULAR signal transduction; COMBINATION drug therapy; CONFIDENCE intervals; EPIDERMAL growth factor; ESOPHAGEAL tumors; IMMUNOHISTOCHEMISTRY; INTRAVENOUS therapy; MEDICAL cooperation; METASTASIS; MONOCLONAL antibodies; MULTIVARIATE analysis; PLACEBOS; POLYMERASE chain reaction; RESEARCH; RESEARCH funding; TUMOR markers; STOMACH tumors; RANDOMIZED controlled trials; TREATMENT effectiveness; BLIND experiment; DISEASE progression; KAPLAN-Meier estimator; PROGNOSIS
- Publication
Oncologist, 2016, Vol 21, Issue 9, p1085
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1634/theoncologist.2016-0038